U3-1402: Ph I/II started

Daiichi Sankyo began an open-label, Japanese Phase I/II trial of IV U3-1402 every 3 weeks in about 80 patients. A dose-escalation part will evaluate 1.6-9.7 mg/kg U3-1402 in patients who are refractor...